CN

You Are Leaving Avistone's Website

You have selected a link that will take you to a site maintained by a third party. Avistone provides this link as a service to website visitors. Avistone is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Click 'Cancel' to return to Avistone's site or 'Continue' to proceed.

Cancel Continue
NEWS

NEWS

Celebrating Vebreltinib's 2025 NRDL Inclusion for MET Amplification: Boosting Support for NSCLC Patients

2025-12-07

Celebrating Vebreltinib's 2025 NRDL Inclusion for MET Amplification: Boosting Support for NSCLC Patients

On December 7, 2025, a major positive update was announced regarding China’s National Reimbursement Drug List (2025): Vebreltinib Enteric Capsules, hereinafter referred to as "Vebreltinib", a novel MET inhibitor developed by Beijing Pearl Biotechnology Co., Ltd—a wholly-owned subsidiary of Beijing Avistone Biotechnology Co., Ltd.—has been successfully included in the national medical insurance drug list for its newly added indication in 2025: "for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition factor (MET) amplification"[1]. This marks the third milestone for Vebreltinib following its inclusion in the medical insurance list in 2024 for two indications—NSCLC with MET exon 14 skipping mutation and glioma[2]. The latest inclusion will further expand the coverage of precision therapy for MET abnormalities, bringing new treatment options to more NSCLC patients with MET amplification.

View Details
Congratulations on Vebreltinib's inclusion in the Expert Consensus on Targeted and Immunotherapy for Gliomas (2025 Edition), Facilitating Standardized and Precision-based Diagnosis and Treatment of Gliomas in China

2026-01-05

Congratulations on Vebreltinib's inclusion in the Expert Consensus on Targeted and Immunotherapy for Gliomas (2025 Edition), Facilitating Standardized and Precision-based Diagnosis and Treatment of Gliomas in China

Vebreltinib Enteric Capsules, a MET inhibitor developed by Beijing Pearl Biotechnology Co., Ltd., a wholly-owned subsidiary of Beijing Avistone Biotechnology Co., Ltd. (Avistone), has been included in the Expert Consensus on Targeted and Immunotherapy for Gliomas (2025 Edition), which was published in Chinese Journal of Neurosurgery, Volume 41, Issue 12, December 2025¹.

View Details
【New Year Start · Medical Insurance Safeguard】The inclusion of Vebreltinib for MET-amplified NSCLC indication in the medical insurance scheme officially takes effect today, marking a new level of accessibility for precision therapy!

2026-01-01

【New Year Start · Medical Insurance Safeguard】The inclusion of Vebreltinib for MET-amplified NSCLC indication in the medical insurance scheme officially takes effect today, marking a new level of accessibility for precision therapy!

New Year Dawns, Warm Blessings Arrive! Starting today (January 1, 2026), the newly updated 2025 National Reimbursement Drug List for Basic Medical Insurance, Maternity Insurance and Work-related Injury Insurance (hereinafter referred to as the National Reimbursement Drug List) has officially come into force. Vebreltinib Enteric-coated Capsules, hereinafter referred to as "Vebreltinib", a novel MET inhibitor developed by Beijing Pearl Biotechnology Co., Ltd., a wholly-owned subsidiary of Beijing Avistone Biotechnology Co., Ltd. (Avistone Biotech), has been successfully included in the scope of medical insurance reimbursement for its indication in the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition factor (MET) amplification[1]. This brings the first ray of health hope to numerous patients in the new year!

View Details
Avistone Wins Top Award in Future Health at the "2025 National Unicorn Enterprise Competition"

2025-12-16

Avistone Wins Top Award in Future Health at the "2025 National Unicorn Enterprise Competition"

From December 10 to 14, the National Finals of the 2025 National Unicorn Enterprise Competition (The First Competition) concluded successfully in Ningbo, Zhejiang. In this national-level competition for high-growth enterprises, Beijing Avistone Biotechnology Co., Ltd. (Avistone) demonstrated exceptional strength across multiple dimensions, including innovation capability, growth potential, integrated business models, valuation prospects, and financial performance. Avistone not only won the competition’s highest honor—the "Excellence Award," but also ranked first among all award-winning enterprises in the Future Health sector.

View Details
< 12345 >